Publication:
Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study

Simple item page
dc.contributor.authorsBasaran, Gul Atalay; Guney, Nese; Saip, Pinar; Iyikesici, Salih; Kaya, Handan; Yazici, Hulya; Serdar, Turhal N.
dc.date.accessioned2022-03-12T15:59:24Z
dc.date.accessioned2026-01-10T21:02:37Z
dc.date.available2022-03-12T15:59:24Z
dc.date.issued2006
dc.identifier.doidoiWOS:000248078900241
dc.identifier.eissn1569-8041
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/11424/224396
dc.identifier.wosWOS:000248078900241
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofANNALS OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleSerum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage91
oaire.citation.startPage90
oaire.citation.titleANNALS OF ONCOLOGY
oaire.citation.volume17

Files

Collections

Araştırma Çıktıları